Alphamab Oncology Reports First Patient Dosed in Phase III Cervical Cancer Study
Alphamab Oncology says the first patient has been dosed in a Phase III study of JSKN033 monotherapy for cervical cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.